glp 1 agonists vs sglt2 inhibitors and GLP-1 receptor agonists: a sound combination Choosing SGLT2 Inhibitors vs GLP-1

Summary Pulling the new reports together, there is further momentum and excitement building for GLP-1 drug expanded use beyond diabetes and obesity

The retrospective, nonrandomized design prevents us from separating the effect of weight loss per se from changes in dietary intake (which by itself could affect 24-hour urine parameters)

Med Rev 2024;4(4):30111 Heymsfield SB, Gonzalez MC, Shen W, Redman L, Thomas D (2014) Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule

[DOI] [PubMed] [Google Scholar] 124.Durak A., Olgar Y., Degirmenci S., Akkus E., Tuncay E., Turan B

It is associated with insulin resistance as seen in type 2 diabetes mellitus

Dulaglutide The AWARD-7 study assessed the efficacy and safety of dulaglutide in T2D patients with moderate-to-severe CKD (Tuttle et al., 2018)